Eterna Therapeutics (ERNA) announced that it has entered into an exclusive option and license agreement with Lineage Cell Therapeutics (LCTX) for the development of novel induced hypoimmune pluripotent stem cell lines, which Lineage will evaluate for development into cell transplant therapies. The new cell lines to be developed by Eterna will support the potential creation of additional product candidates at Lineage, specifically for the treatment of certain central nervous system disorders and other neurology indications. Eterna is the exclusive licensee of the key intellectual property underlying this collaboration. "The cell therapy expertise demonstrated by Lineage makes them an attractive partner to deploy our mRNA cell engineering platform for the generation of novel gene-edited iPSC lines for neurological applications," said Matt Angel, Ph.D., CEO of Eterna. "At Eterna, we have expertise in creating gene-edited iPSC lines using our extensively patented mRNA cell engineering technologies. We look forward to collaborating with the Lineage team on this project and working with them to develop these powerful tools for the generation of new, intelligently-engineered cell therapy product candidates in the CNS space." Under the Agreement, Eterna plans to conduct certain gene-editing activities and provide materials to Lineage for evaluation. The Agreement provides Lineage an option to obtain an exclusive license to utilize and sublicense the novel gene-edited cell lines for preclinical, clinical, and commercial purposes in the field of CNS diseases. Financial terms were not disclosed.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ERNA:
